A detailed history of Morgan Stanley transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 167,916 shares of CMPX stock, worth $303,927. This represents 0.0% of its overall portfolio holdings.

Number of Shares
167,916
Previous 164,231 2.24%
Holding current value
$303,927
Previous $325,000 48.62%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.0 - $1.85 $3,685 - $6,817
3,685 Added 2.24%
167,916 $167,000
Q1 2024

Aug 16, 2024

SELL
$1.2 - $2.29 $76,510 - $146,008
-63,759 Reduced 27.97%
164,231 $325,000
Q1 2024

May 15, 2024

SELL
$1.2 - $2.29 $76,510 - $146,008
-63,759 Reduced 27.97%
164,231 $325,000
Q4 2023

Aug 16, 2024

BUY
$1.4 - $1.98 $84,103 - $118,946
60,074 Added 35.78%
227,990 $355,000
Q4 2023

Feb 13, 2024

BUY
$1.4 - $1.98 $230,581 - $326,107
164,701 Added 260.24%
227,990 $355,000
Q3 2023

Nov 15, 2023

SELL
$1.87 - $3.25 $103,985 - $180,722
-55,607 Reduced 46.77%
63,289 $124,000
Q2 2023

Aug 14, 2023

SELL
$2.64 - $3.48 $108,683 - $143,264
-41,168 Reduced 25.72%
118,896 $378,000
Q1 2023

May 15, 2023

BUY
$3.14 - $5.48 $300,077 - $523,701
95,566 Added 148.17%
160,064 $523,000
Q4 2022

Feb 14, 2023

BUY
$2.55 - $5.41 $141,846 - $300,936
55,626 Added 626.98%
64,498 $324,000
Q3 2022

Nov 14, 2022

BUY
$1.9 - $3.37 $15,692 - $27,832
8,259 Added 1347.31%
8,872 $20,000
Q2 2022

Oct 27, 2022

SELL
$1.43 - $3.1 $37,700 - $81,728
-26,364 Reduced 97.73%
613 $2,000
Q2 2022

Aug 15, 2022

SELL
$1.43 - $3.1 $37,700 - $81,728
-26,364 Reduced 97.73%
613 $2,000
Q1 2022

Oct 27, 2022

BUY
$1.25 - $3.5 $32,955 - $92,274
26,364 Added 4300.82%
26,977 $37,000
Q1 2022

May 13, 2022

BUY
$1.25 - $3.5 $11,880 - $33,264
9,504 Added 54.39%
26,977 $37,000
Q4 2021

Feb 14, 2022

BUY
$2.88 - $3.98 $50,322 - $69,542
17,473 New
17,473 $56,000

Others Institutions Holding CMPX

About Compass Therapeutics, Inc.


  • Ticker CMPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 101,285,000
  • Market Cap $183M
  • Description
  • Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...
More about CMPX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.